The effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss During Immobilisation

Male

Aged from 18-35 years

18.5 < BMI < 30 kg/m2

 (Family) history of thromboembolic events

 Smoking

 Recent surgery (within 6 months prior to the study)

 Performing progressive resistance training more than three times per week in the past year

 Any back/leg/knee/shoulder complaints which may interfere with the use of crutches

 Current systemic use of corticosteroids, anabolic steroids, growth hormone, testosterone, nandrolone, protein supplements, immunosuppressants or insulin, blood sugar decreasing medication or EPO

 All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis)

 Use of anti-coagulants

 Pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate)

 Liver disease

 Heart failure

 Migraine

 Allergy to nuts or soy

 High blood pressure (>140 mmHg systolic and >90 mmHg diastolic)